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‘Go Slow’ myopathy (GSM) is an idiopathic myopathy in dogs in New Zealand, 
characterised by an acute onset of trembling, weakness and collapse, followed by a 
prolonged period of exercise intolerance. In the first part of this thesis, the 
epidemiology of the disease was investigated using a telephone survey to obtain 
information regarding the diet, exercise, and health of affected dogs. Eighty-six 
confirmed cases were included in this study, and ingestion of wild pig in the week prior 
to the onset of clinical signs was a consistent finding (76/86 dogs; 88%; 95% confidence 
interval = 82 – 95%). Cases occurred most commonly in the upper North Island, 
particularly in Northland.  
 
The aim of the second part of this thesis was to characterise the pathology of GSM in 
the same 86 dogs included in the epidemiological study, using serum biochemistry (78 
dogs), histology (20 dogs), and electron microscopy (4 dogs). Acutely, affected dogs 
had increased serum creatine kinase and aspartate aminotransferase activities, 
corresponding with the histological finding of skeletal muscle degeneration in the 
absence of inflammation. Ultrastructural changes in skeletal muscle included 
mitochondrial hypertrophy, intramitochondrial inclusions and increased sarcoplasmic 
glycogen. Similar lesions were observed in the skeletal muscle of wild pigs from areas 
where GSM occurred in dogs. Affected dogs also had increased serum alanine 
aminotransferase activities due to accumulation of lipid and glycogen in hepatocytes. 
Overall, the microscopic findings were consistent with a toxic myopathy.  
 
To further investigate the pathogenesis of the disease, liver samples were collected 
from 15 affected dogs and 24 clinically normal dogs for untargeted metabolic profiling 
using liquid chromatography-mass spectrometry. Comparison of spectra between 
affected and normal dogs revealed a widespread decrease in phospholipids, and 
increases in selected dicarboxylic acids and N-acetylated branch chain amino acids in 
affected dogs. No causative compounds were identified although several candidate 





Taken together, the results of these studies suggest that ‘Go Slow’ myopathy is a toxic 
mitochondrial myopathy in dogs that is associated with the ingestion of wild pork. The 
findings reported aid in the prevention, diagnosis, and management of cases, with the 
primary suggestion being that owners avoid feeding wild pork in areas where the 
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